Cinqair approved for severe asthma
Wednesday, March 23, 2016 - 16:00
in Health & Medicine
HealthDay News Reslizumab, sold as Cinqair, has been approved by the U.S. Food and Drug Administration to treat severe asthma among adults 18 and older.